Reference 2017-335

REF:            2017-335

Subject:        Dermatology drugs

 

 

Request:

I have a Freedom of Information request regarding biologics and biosimilar prescribing.

 

Could you please provide me with the numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs within the dermatology or gastroenterology departments?

 

 

 

Response:

Below is the number of patients treated in Dermatology and Gastroenterology for the listed drugs. These figures also include Homecare patients.
  Dermatology Gastroenterology
Abatacept (Orencia) 0 0
Adalimumab (Humira) 0 177
Apremilast (Otezla) 6 0
Certolizumab Pegol (Cimzia) 0 0
Etanercept (Enbrel) 0 0
Etanercept biosimilar (Benepali) 0 0
Fumaric Acid Esters 34 N/A
Golimumab (Simponi) 0 0
Infliximab (Remicade) 0 81
Infliximab biosimilar (Inflectra) 0 47
Infliximab biosimilar (Remsima) 0 96
Rituximab (MabThera) 0 0
Secukinumab (Cosentyx) 0 0
Ixekizumab (Taltz) 0 0
Tocilizumab (RoActemra) 0 0
Ustekinumab (Stelara) 0 0
Vedolizumab (Entyvio) 0 35